Author

T. Yokoyama

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC

The combination of DFP-14323 and low-dose afatinib was considered to have the potential for future clinical utility for EGFR mutation-positive NSCLC and is evaluating this combination therapy in uncommon EGFR mutation-positive NSCLC in Japan.

Hiroshige Yoshioka, Masahide Mori, N. Katakami et al. · Therapeutic Advances in Medi... · 0 citations

Open access Aug 2026

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis

Nivolumab plus ipilimumab-based therapies have shown long-term, durable clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC), including those with tumor programmed death-ligand 1 (PD-L1) expression < 1%, a population with high unmet need. Here we report long-term clinical outcomes with first-...

Makoto Nishio, H. Hayashi, Yasushi Goto et al. · International Journal of Cli... · 0 citations

Open access Jul 2026

Osimertinib vs. erlotinib combined with an angiogenesis inhibitor in EGFR-mutated non-small cell lung cancer with malignant pleural effusion: a retrospective cohort study

Background Osimertinib is the standard first-line treatment for non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. Erlotinib plus an angiogenesis inhibitor (erlotinib+A) has demonstrated efficacy in controlling malignant pleural effusion (MPE) through reduction of vascular...

T. Hata, T. Yamada, Koji Mikami et al. · Translational Lung Cancer Re... · 0 citations